** Drug developer's shares down 7 pct at $34.10premarket
** University of Geneva Hospital says study of experimentalEbola vaccine being developed by NewLink Genetics and Merck & CoInc interrupted in all 59 volunteers
** Hospital says 4 patients complained of joint pains inhand and feet; study of vaccine is scheduled to resume on Jan. 5in up to 15 volunteers after checks to see if pain symptoms were"benign and temporary"
** GlaxoSmithKline Plc is developing its own Ebolavaccine with National Institutes of Health; plans to build astockpile for emergency deployment
** Take A Look - World on alert to curb Ebola outbreak
Glaxosmithkline (GSK)